Vertex Achieves Gene-Editing Milestone With First Ever CRISPR Therapy Approval
Executive Summary
Great Britain is first to approve the groundbreaking CRISPR-based therapy for sickle cell and beta thalassemia. Vertex is yet to reveal its price, however, and wants to play down early expectations of its commercial potential.
You may also be interested in...
UK Authorizes Vertex’s Casgevy, The World’s First CRISPR/Cas9 Gene Therapy
Vertex’s Casgevy has made history as the world’s first approved CRISPR gene editing therapy after the UK’s MHRA authorized the medicine ahead of its US and European regulatory counterparts.
Gene Editing: Exa-Cel Panel Review Raises Practical Concerns About Theoretical Risks
US FDA advisory committee members questioned how potential off-target effects with Vertex’s gene therapy for sickle cell disease should be conveyed to patients and families, and whether labeling should say anything about these theoretical risks.
Vertex Gears Up For Major Milestones, Starting With Sickle Cell Launch And Pain Drug Readout
Having long attracted investors thanks to its promising pipeline, the moment of truth approaches for Vertex’s sickle cell gene therapy exo-cel, and VX-548, which has potential to transform acute and chronic pain treatment.